(Reuters) (Reuters) Mind Medicine Inc. was placed on hold in clinical trial by the U.S. Food and Drug Administration. The company wanted to test LSD for patients suffering from generalized anxiety disorder.
Canada-based drug developer stated Tuesday that the FDA hold was caused by the FDA’s investigational new drug request. This request is needed to start a mid-stage study of the drug Lysergic acid Diethylamide.
The reason for the delay is not yet identified. Mind Medicine said more details regarding the FDA’s decision were to be announced within 30 days.
The FDA’s latest move is a blow to the industry of psychedelics that tries to make use of LSD or other compounds like the psilocybin to treat ailments.
Compass Pathways shares fell 16 percent in November owing to safety concerns regarding its experimental drug COMP360. The drug is the psychedelic active ingredient in magic mushrooms to combat depression.
Content Source: https://www.medscape.com/viewarticle/965285?src=rss
